Depomed Inc (DEPO) 19.31 $DEPO Downgrade Alert for

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 4:09 PM

Depomed Inc (DEPO) 19.31 $DEPO

Downgrade Alert for Depomed (DEPO)
Comtex SmarTrend(R) - Thu Jul 28, 3:29AM CDT
Depomed (NASDAQ

EPO) was downgraded from Overweight to Neutral at Piper Jaffray today. The stock closed yesterday at $18.70 on volume of 1.2 million shares, below average daily volume of 2.2 million. Depomed (NASDAQ

EPO) has potential upside of 56.0% based on a current price of $18.70 and analysts' consensus price target of $29.17. The stock should hit resistance at its 200-day moving average (MA) of $19.87, as well as support at its 50-day MA of $15.49.
DEPO: 19.31 (+0.34)

Depomed to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, August 3, 2016
GlobeNewswire - Wed Jul 27, 3:08PM CDT
Depomed, Inc. (NASDAQ

EPO) today announced that it will release second quarter fiscal year 2016 financial results after the close of market, Wednesday, August 3, 2016. The Company will host a conference call beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results.
DEPO: 19.31 (+0.34)

Starboard Delivers Letter To Depomed Shareholders
PR Newswire - Tue Jul 26, 8:13AM CDT
Starboard Value LP (together with its affiliates, "Starboard"

, one of the largest shareholders of Depomed, Inc. (NASDAQ: DEPO) with an ownership interest in approximately 9.9% of Depomed's outstanding shares, today announced it has delivered an open letter to Depomed shareholders.
DEPO: 19.31 (+0.34)

Coverage Initiated on Select Drug Manufacturers' Stocks
ACCESSWIRE - Fri Jul 15, 8:16AM CDT
LONDON, UK / ACCESSWIRE / July 15, 2016 / Active Wall St. announces the list of stocks for today's coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers - Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. See our complete notes on Ionis Pharma at:
UTHR: 124.94 (+3.93), AMRN: 2.91 (+0.26), DEPO: 19.31 (+0.34), IONS: 38.10 (+8.91)

Featured Research Report on Drug Manufacturers Stocks
ACCESSWIRE - Tue Jun 14, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 14, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers-Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
UTHR: 124.94 (+3.93), AMRN: 2.91 (+0.26), DEPO: 19.31 (+0.34), IONS: 38.10 (+8.91)

Depomed Issues Statement in Response to Starboard's Press Release
GlobeNewswire - Thu May 26, 10:17AM CDT
Depomed, Inc. (NASDAQ

EPO) ("Depomed" or the "Company"

today issued the following statement in response to Starboard Value LP's ("Starboard"

latest press release.
DEPO: 19.31 (+0.34)

Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Deterrent Potential and a Favorable Respiratory Profile
GlobeNewswire - Mon May 23, 7:00AM CDT
Depomed, Inc. (NASDAQ

EPO) today announced that clinical data from Phase IIb trials of cebranopadol in chronic lower back pain (cLBP) and diabetic peripheral neuropathy (DPN) as well as from the human abuse potential and respiratory depression studies conducted by Grunenthal GmbH ("Grunenthal"

were presented this weekend at the 8th World Congress of the World Institute of Pain (WIP) in New York, New York. Cebranopadol is a novel, first-in-class analgesic in development for the treatment of moderate to severe chronic nociceptive and neuropathic pain. In December 2015, Depomed acquired the U.S. and Canadian rights to cebranopadol from Grunenthal.
DEPO: 19.31 (+0.34)

Depomed Announces District Court Order Extending Stay in NUCYNTA ANDA Litigation
GlobeNewswire - Wed May 18, 3:45PM CDT
Depomed, Inc. (Nasdaq

EPO) today announced that on May 18, 2016, Judge Claire C. Cecchi of the United States District Court for the District of New Jersey entered an order enjoining any of Actavis Elizabeth LLC, Actavis LLC and Actavis Inc. (collectively, "Actavis"

, Alkem Laboratories Limited and Ascend Laboratories (together, "Alkem"

, Roxane Laboratories, Inc. ("Roxane"

, and Watson Laboratories, Inc. ("Watson"

from marketing generic versions of any of NUCYNTA, NUCYNTA ER or NUCYNTA oral solution prior to the Court's issuance of a decision in the pending patent litigation. The U.S. patents asserted in the consolidated action are: RE39,593; 7,994,364; and 8,536,130, which currently expire on August 5, 2022, June 27, 2025, and September 22, 2028, respectively. An additional six months of patent protection is expected for these patents upon issuance of pediatric exclusivity from the FDA. Judge Cecchi's order states that she expects to render a decision on this matter no later than September 30, 2016.
DEPO: 19.31 (+0.34)

Depomed Announces Presentation of Cebranopadol Data at World Institute of Pain Congress
GlobeNewswire - Mon May 16, 7:00AM CDT
Depomed, Inc. (NASDAQ

EPO) today announced that clinical data from two Phase IIb trials as well as human abuse potential and respiratory depression studies conducted by Grunenthal GmbH ("Grunenthal"

will be presented at the 8th World Congress of the World Institute of Pain (WIP) to be held May 20-23, 2016 at the New York Hilton Hotel in New York, New York. Cebranopadol is a novel, first-in-class analgesic in development for the treatment of moderate to severe chronic nociceptive and neuropathic pain. In December 2015, Depomed acquired the U.S. and Canadian rights to cebranopadol from Grunenthal.
DEPO: 19.31 (+0.34)

Upgrade Alert for Depomed (DEPO)
Comtex SmarTrend(R) - Tue May 10, 3:45AM CDT
Depomed (NASDAQ

EPO) was upgraded from Neutral to Buy at Mizuho today. The stock closed yesterday at $17.85 on volume of 4.4 million shares, above average daily volume of 2.2 million. There is potential upside of 63.4% for shares of Depomed based on a current price of $17.85 and an average consensus analyst price target of $29.17. Depomed shares should encounter resistance at the 200-day moving average (MA) of $19.87 and support at the 50-day MA of $15.49.
DEPO: 19.31 (+0.34)

Depomed reports 1Q loss
Automated Insights - Thu May 05, 4:34PM CDT
NEWARK, Calif. (AP) _ Depomed Inc. (DEPO) on Thursday reported a loss of $20.9 million in its first quarter.
DEPO: 19.31 (+0.34)

Depomed Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:00PM CDT
- First Quarter Revenues of $105M, up 225% over 1Q 2015 -
DEPO: 19.31 (+0.34)

What Caused DepoMed's Shares to Skyrocket 20.9% In April
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 11:40AM CDT
SOURCE: FLICKR USER STOCKMONKEYS.COM. What: After activist investor Starboard Value LP took a nearly 10% stake in DepoMed , the company's shares soared 20.9% last month, according to data from S&P Global Market Intelligence . So what:...
HZNP: 18.64 (-0.65), DEPO: 19.31 (+0.34)

Depomed to Present at Healthcare Conferences in May
GlobeNewswire - Tue May 03, 7:00AM CDT
Depomed, Inc. (NASDAQ

EPO) today announced that it will be presenting at the following healthcare conferences during the month of May.
DEPO: 19.31 (+0.34)

Depomed to Report First Quarter Fiscal Year 2016 Financial Results on Thursday, May 5, 2016
GlobeNewswire - Thu Apr 28, 7:00AM CDT
Depomed, Inc. (NASDAQ

EPO) today announced that it will release first quarter fiscal year 2016 financial results after the close of market, Thursday, May 5, 2016. The Company will host a conference call beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results.
DEPO: 19.31 (+0.34)

4 Bargain Stocks You Can Buy Today
Todd Campbell, Jason Hall, Andrés Cardenal, and Steve Symington, The Motley Fool - Motley Fool - Wed Apr 27, 11:16AM CDT
Image source: Flickr user Elliott Brown. The market is always offering up stocks in its bargain bin, but that doesn't necessarily mean every stock that's on sale is worth buying. We asked some of our top Motley Fool contributors to weigh in with...
IBM: 161.16 (+0.54), DEPO: 19.31 (+0.34), CLNE: 2.85 (-0.14), PCLN: 1,354.75 (+3.94)

Depomed gives Starboard chance for meeting to replace board
By The Associated Press - AP - Mon Apr 25, 10:02AM CDT
Depomed is taking another step to avoid the pain of a protracted fight with activist investor Starboard Value over control of the drugmaker.
DEPO: 19.31 (+0.34), DRI: 61.65 (+0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...